GlassScriptPhysician profile
Jonathan M Frantz
NPI 1861494742
$6,458.91
in general payments reported to CMS, 2019-2025
25 companies · $505 in 2025
The $505 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,276 · 2020: $554 · 2021: $1,682 · 2022: $995 · 2023: $842 · 2024: $604 · 2025: $505.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,889 · Gift: $36.07 · Honoraria: $25.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,889.36 |
| Gift | $36.07 |
| Honoraria | $25.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $2,496.44 | 2019-2025 | Clareon, Clareon Panoptix Pro, Centurion |
| Rxsight INC | $1,026.92 | 2021-2025 | Rxsight Contact Lens, Rxsight Injector Cartridge, Rxsight Light Delivery Device (Ldd) |
| Allergan, INC. | $412.46 | 2019-2022 | |
| Johnson & Johnson Surgical Vision, INC. | $299.64 | 2019 | |
| Omeros Corporation | $299.39 | 2019-2021 | |
| Rayner Intraocular Lenses Limited | $281.73 | 2022-2024 | Rayone Spheric, Rayone Emv, Omidria |
| Biotissue Holdings INC. | $262.41 | 2024 | |
| Carl Zeiss Meditec USA, INC. | $187.07 | 2021-2025 | Visumax |
| Dompe US, INC. | $176.11 | 2022-2025 | Oxervate |
| Staar Surgical Company | $167.99 | 2019 | |
| Merz North America, INC. | $157.31 | 2023 | Xeomin |
| Abbvie INC. | $137.48 | 2023-2025 | |
| Carl Zeiss Meditec, INC. | $126.11 | 2019 | |
| Glaukos Corporation | $101.15 | 2020-2022 | |
| Sun Pharmaceutical Industries INC. | $76.10 | 2019-2020 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Halozyme INC | $51.47 | 2019-2021 | |
| Coopervision INC. | $43.41 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $31.95 | 2023 | |
| Ivantis, INC | $23.01 | 2021 | |
| Ocular Therapeutix, INC. | $21.97 | 2024 | Dextenza |
| Oyster Point Pharma, INC. | $21.43 | 2022 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Lensar, INC. | $17.25 | 2020 | |
| Iridex Corporation | $16.22 | 2019 | |
| Lombart Brothers, INC. | $4.49 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Frantz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.